Sustained Efficacy and Safety in C3 Glomerulopathy Following 36 Months of Oral Treatment with Iptacopan: Interim Participant Results from the APPEAR-C3G Extension Study (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-OR078; Pres time: Oct 24, 2026; 05:30 PM - 05:42 PM; Location: Four Seasons Ballroom 2; No abstract available
Clinical • Late-breaking abstract • Complement-mediated Rare Disorders • Glomerulonephritis
|
|
Carla M. Nester; Richard J. Smith; David Kavanagh; Marina Vivarelli; Giuseppe Remuzzi; Minghui Zhao; Edwin K. Wong; Shiwei Cao; Rubeen K. Israni; Raquel Luna Yolba; Severina Jacinto-Sanders; Jean Grisouard; Andrew S. Bomback
|